Tadalafil-SZ in the treatment of premature ejaculation in young age men: a comparative placebo-controlled study

BACKGROUND: The frequency of occurrence reaches premature ejaculation (PE) in young men reaches 30%. Increasing the effectiveness of treatment of patients with PE is one of the important problems of urology.

AIM: Evaluation of the effectiveness of treatment of young patients with premature ejaculation with the phosphodiesterase 5-type inhibitor Tadalafil-SZ in monotherapy and in combination with behavioral therapy, as well as its comparison with the appointment of only behavioral therapy and placebo.

MATERIALS AND METHODS: We observed 70 men with premature ejaculation aged 18 to 25 years. All patients were divided into 4 groups. Patients of the 1^st group (n = 20) were prescribed Tadalafil-SZ at a dose of 5 mg once a day as monotherapy, patients of the 2^nd group (n = 20) received behavioral therapy according to the “start–stop” method; patients of the 3^rd group (n = 20) were prescribed a combination therapy with Tadalafil-SZ at a dose of 5 mg per day together with the “start–stop” behavioral technique; patients of the 4^th group (n = 10) were prescribed a placebo. The duration of treatment is 30 days. Control examinations were performed before the start of treatment, immediately after its completion and 2 months after the end of therapy. To assess ejaculatory function the PEDT and AIPE questionnaires were used, as well as the IELT test.

RESULTS: After the end of the 30-day course of treatment in patients of the 1^st and 3^rd groups, a significant increase in the duration of sexual intercourse by 2–2.5 times was noted compared with the values before treatment, as well as with the values in patients of the 4^th group who received placebo. In patients of the 2^nd group, we did not notice significant changes in comparison with the indicators before treatment in terms of the total scores of the PEDT questionnaire and the results of the IELT test, however, an increase in the total scores of the AIPE questionnaire was found. In patients of the 4^th control group, there was no improvement in any of the tests performed. 2 months after the end of treatment, patients of the 1^st group noted a return to the initial duration of sexual intercourse. The effect of the treatment was noted only in patients of the 3^rd group, in whom during the control examination after 2 months the duration of sexual intercourse was significantly higher compared to the initial values before the start of treatment.

CONCLUSIONS: The results of the study indicate the high efficiency of the phosphodiesterase 5-type inhibitor Tadalafil-SZ in the treatment of patients with premature ejaculation. The best results of treatment were achieved with the combined use of drug and behavioral therapy.